Syndax Pharmaceuticals (SNDX) Net Income towards Common Stockholders: 2015-2020
Historic Net Income towards Common Stockholders for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Dec 2020 value amounting to -$19.9 million.
- Syndax Pharmaceuticals' Net Income towards Common Stockholders fell 39.81% to -$19.9 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$71.4 million, marking a year-over-year decrease of 24.13%. This contributed to the annual value of -$318.8 million for FY2024, which is 52.25% down from last year.
- Per Syndax Pharmaceuticals' latest filing, its Net Income towards Common Stockholders stood at -$19.9 million for Q4 2020, which was down 0.04% from -$19.9 million recorded in Q3 2020.
- In the past 5 years, Syndax Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of -$8.4 million in Q2 2016 and a low of -$19.9 million during Q4 2020.
- Its 3-year average for Net Income towards Common Stockholders is -$17.1 million, with a median of -$17.2 million in 2018.
- In the last 5 years, Syndax Pharmaceuticals' Net Income towards Common Stockholders crashed by 145.93% in 2016 and then rose by 26.52% in 2019.
- Over the past 5 years, Syndax Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at -$10.9 million in 2016, then crashed by 74.99% to -$19.0 million in 2017, then decreased by 1.61% to -$19.3 million in 2018, then increased by 26.52% to -$14.2 million in 2019, then plummeted by 39.81% to -$19.9 million in 2020.
- Its Net Income towards Common Stockholders was -$19.9 million in Q4 2020, compared to -$19.9 million in Q3 2020 and -$16.6 million in Q2 2020.